Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Βιοτεχνολογία

Ms. Karen  McGrath

Chief People Officer

Mr. Randall B. Brenner

Chief Devel. & Regulatory Officer

Ms. Sarah  Higgins

Vice President of Fin., Controller & Principal Accounting Officer

Mr. William M. Haskel

Senior Vice President, Chief Legal Officer, Gen. Counsel & Corporation Sec.

Mr. Jonathan  Light

Deputy Gen. Counsel & Chief Compliance Officer

Mr. Michael F. Bigham C.P.A., CPA, M.B.A., MBA

Executive Chairman

Senior Vice President of HR

Senior Vice President, Chief Legal Officer, Gen. Counsel, Corporation Sec. & Chief Compliance Officer

Mr. Ben  Strain

Vice President of Investor Relations & Corporation Communications and Chief of Staff to the Chief Executive Officer

Όνομα	Κεφαλαιοποίηση αγοράς
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M

Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc.Λίστα ανταγωνιστών

Κύριοι ανταγωνιστές